Tiotropium in the Treatment of the Patients With Chronic... | NCT02177318 | Trialant

Tiotropium in the Treatment of the Patients With Chronic... | NCT02177318 | Trialant

Arms/Interventions Module

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Spiriva (tiotropium bromide) inhalation capsules	Drug	Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules	Patients with COPD

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of patients with adverse events		Up to 4 weeks after start of treatment
Number of patients with adverse drug reactions		Up to 4 weeks after start of treatment
Number of patients with serious adverse events		Up to 4 weeks after start of treatment

Secondary Outcomes

Measure	Description	Time Frame
Physician's overall judgement by medical interview into four grades: 1. Improved 2. No Change 3. Aggravated 4.Unassessable		Up to 4 weeks after start of treatment

Contacts/Locations Module

Ancestor Terms

ID	Term
D008173	Lung Diseases, Obstructive
D008171	Lung Diseases
D012140	Respiratory Tract Diseases
D002908	Chronic Disease
D020969	Disease Attributes
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms

Ancestor Terms

ID	Term
D012602	Scopolamine Derivatives
D014326	Tropanes
D053961	Azabicyclo Compounds
D001372	Aza Compounds
D009930	Organic Chemicals
D000470	Alkaloids
D006571	Heterocyclic Compounds
D019086	Bridged Bicyclo Compounds, Heterocyclic
D006572	Heterocyclic Compounds, Bridged-Ring
D015656	Respiratory Mechanics
D012119	Respiration
D012143	Respiratory Physiological Phenomena
D002943	Circulatory and Respiratory Physiological Phenomena